From Medscape Oncology

Coverage from the

Gastrointestinal Cancers Symposium (GICS) 2022

January 20 - 22, 2022; San Francisco, CA and Virtual/Online

January 20 - 22, 2022 San Francisco, CA and Virtual/Online

GICS 2022 Dual Immunotherapy Promising New Option for Liver Cancer The combination of durvalumab plus the experimental drug tremelimumab significantly improved overall survival as compared to sorafenib.
Medscape Medical News, January 24, 2022

Conference News

GICS 2022 Decades of Research Fail to Resolve Disparities in GI Cancer Care
Medscape Medical News, January 27, 2022
GICS 2022 Endoscopic Mucosal Resection Valuable for Cancer Diagnosis
Medscape Medical News, January 27, 2022
GICS 2022 Novel Treatment Shows Early Promise for Gastric Cancer
Medscape Medical News, January 27, 2022
GICS 2022 Can Immunotherapy Replace Surgery for Stomach Cancer?
Medscape Medical News, January 27, 2022
GICS 2022 Oxaliplatin Add-On Not Recommended for Elderly With Colon Cancer
Medscape Medical News, January 27, 2022
GICS 2022 ctDNA Identifies CRC Patients Who Benefit From Adjuvant Therapy
Medscape Medical News, January 26, 2022
GICS 2022 Adding TACE to Lenvatinib Improves Survival in Liver Cancer
Medscape Medical News, January 25, 2022
Potential New Standard of Care for Biliary Tract Cancer
Medscape Medical News, January 24, 2022
GICS 2022 Dual Immunotherapy Promising New Option for Liver Cancer
Medscape Medical News, January 24, 2022
Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer
Medscape Medical News, January 21, 2022

Popular News from GICS 2021

Novel Blood Test Detects Precancerous Colorectal Adenomas A novel multiomics blood test was shown to detect advanced colorectal adenomas at comparable or better rates than currently available stool tests.
Medscape Medical News, Jan 21, 2021
New Standard for Borderline Resectable Pancreatic Cancer Neoadjuvant mFOLFIRINOX was associated with favorable overall survival compared to historical data, but the addition of hypofractionated radiotherapy did not improve outcomes.
Medscape Medical News, Jan 20, 2021
Key Presentations on Gastrointestinal Cancers From ASCO 2021 Dr John Marshall highlights presentations on GI cancers from ASCO 2021, including positive results from immunotherapy trials in upper GI cancers and overall survival data from KEYNOTE-177 in mCRC.
Medscape Medical News, Jun 29, 2021

Medscape Oncology©

Perspectives

Three Trials From ASCO GI Renew Hope
Mark A. Lewis, MD

Previous Coverage